167 related articles for article (PubMed ID: 33872258)
1. First Extended-Release Injectable Drug Therapy for HIV.
Aschenbrenner DS
Am J Nurs; 2021 May; 121(5):24-25. PubMed ID: 33872258
[TBL] [Abstract][Full Text] [Related]
2. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
[TBL] [Abstract][Full Text] [Related]
3. Monthly injectable cabotegravir/rilpivirine to manage HIV infection in adults.
Blackwell CW; López Castillo H
J Am Assoc Nurse Pract; 2022 Jul; 34(7):918-923. PubMed ID: 35580282
[TBL] [Abstract][Full Text] [Related]
4. Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV.
Taki E; Soleimani F; Asadi A; Ghahramanpour H; Namvar A; Heidary M
Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1135-1147. PubMed ID: 35596583
[TBL] [Abstract][Full Text] [Related]
5. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
[TBL] [Abstract][Full Text] [Related]
6. Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
Lowenthal ED; Chapman J; Ohrenschall R; Calabrese K; Baltrusaitis K; Heckman B; Yin DE; Agwu AL; Harrington C; Van Solingen-Ristea RM; McCoig CC; Adeyeye A; Kneebone J; Chounta V; Smith-Anderson C; Camacho-Gonzalez A; D'Angelo J; Bearden A; Crauwels H; Huang J; Buisson S; Milligan R; Ward S; Bolton-Moore C; Gaur AH; ;
Lancet HIV; 2024 Apr; 11(4):e222-e232. PubMed ID: 38538161
[TBL] [Abstract][Full Text] [Related]
7. Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection.
Zeuli JD; Rivera CG; Smith BL; Otto A; Temesgen Z
Drugs Today (Barc); 2022 Dec; 58(12):555-576. PubMed ID: 36651065
[TBL] [Abstract][Full Text] [Related]
8. Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy.
Brock JB; Herrington P; Hickman M; Hickman A
Clin Infect Dis; 2024 Jan; 78(1):122-124. PubMed ID: 37740255
[TBL] [Abstract][Full Text] [Related]
9. Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel.
Sax PE; Thompson MA; Saag MS;
JAMA; 2024 Mar; 331(12):1060-1061. PubMed ID: 38427337
[No Abstract] [Full Text] [Related]
10. Cabotegravir and Rilpivirine.
Am J Health Syst Pharm; 2021 May; 78(11):925-931. PubMed ID: 33822851
[No Abstract] [Full Text] [Related]
11. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Orkin C; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Overton ET; Girard PM; Oka S; Walmsley S; Bettacchi C; Brinson C; Philibert P; Lombaard J; St Clair M; Crauwels H; Ford SL; Patel P; Chounta V; D'Amico R; Vanveggel S; Dorey D; Cutrell A; Griffith S; Margolis DA; Williams PE; Parys W; Smith KY; Spreen WR
N Engl J Med; 2020 Mar; 382(12):1124-1135. PubMed ID: 32130806
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the
Han K; Gevorkyan H; Sadik Shaik J; Crauwels H; Leemereise C; Bontempo G; Win B; Chounta V; Seal C; DeMoor R; D'Amico R; Spreen WR; Ford SL
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0078123. PubMed ID: 38038460
[TBL] [Abstract][Full Text] [Related]
13. Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
Garris CP; Czarnogorski M; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR
J Int AIDS Soc; 2022 Sep; 25(9):e26006. PubMed ID: 36097674
[TBL] [Abstract][Full Text] [Related]
14. Long-acting cabotegravir/rilpivirine for HIV-1 treatment: real-world evaluation of barriers to implementation.
Wood BR; Kassaye SG; Gerstoft J
AIDS; 2023 Mar; 37(4):689-691. PubMed ID: 36815522
[No Abstract] [Full Text] [Related]
15. Cabotegravir Plus Rilpivirine: First Approval.
Markham A
Drugs; 2020 Jun; 80(9):915-922. PubMed ID: 32495274
[TBL] [Abstract][Full Text] [Related]
16. Cabotegravir-rilpivirine treatment initiation in a nonvirologically suppressed patient.
Barnett SK; Armas-Kolostroubis L; Sension M; Riedel DJ
AIDS; 2022 Aug; 36(10):1475-1476. PubMed ID: 35876710
[No Abstract] [Full Text] [Related]
17. Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
Courlet P; Alves Saldanha S; Cavassini M; Marzolini C; Choong E; Csajka C; Günthard HF; André P; Buclin T; Desfontaine V; Decosterd LA
J Mass Spectrom; 2020 Jun; 55(6):e4506. PubMed ID: 32160389
[TBL] [Abstract][Full Text] [Related]
18. HIV virologic response and baseline genotypic resistance in a long-acting cabotegravir/rilpivirine initiation program.
Masich AM; Gomes D; Higginson RT; Morgan Z; Nixon D; Tran M; Winthrop E; Fulco PP
AIDS; 2023 Aug; 37(10):1641-1642. PubMed ID: 37450631
[No Abstract] [Full Text] [Related]
19. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
[TBL] [Abstract][Full Text] [Related]
20. Cabotegravir/rilpivirine (Cabenuva) for HIV-1 infection.
Med Lett Drugs Ther; 2021 May; 63(1625):81-83. PubMed ID: 34180282
[No Abstract] [Full Text] [Related]
[Next] [New Search]